Patents Examined by Kahsay Habte
  • Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
    Patent number: 11492348
    Abstract: The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or inhibiting the PI3K-AKT-MTOR pathway, and methods of treating diseases that are associated with autophagy or the PI3K-AKT-MTOR pathway.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: November 8, 2022
    Assignee: Neuropore Therapies, Inc.
    Inventors: Emily M. Stocking, Wolfgang J. Wrasidlo
  • Compounds and methods of use
    Patent number: 11492350
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: November 8, 2022
    Assignee: Tango Therapeutics, Inc.
    Inventors: Kevin M. Cottrell, John P. Maxwell
  • Acid addition salts, compositions, and methods of treating thereof
    Patent number: 11479541
    Abstract: Provided is an acid addition salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine selected from a tartrate salt, a phosphate salt, and a fumarate salt. Also provided are pharmaceutical compositions comprising an acid addition salt disclosed herein and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: October 25, 2022
    Assignee: Pioneura Corporation
    Inventors: Harris A. Gelbard, John M. McCall, Jesse Damsker, Arthur Romero
  • Real-time fluorescence imaging sensor for measuring glutathione in organelle and preparation method therefor
    Patent number: 11472825
    Abstract: The present invention relates to a real-time fluorescence imaging sensor for measuring glutathione in cell organelles and a method for fabricating the same. More specifically, the present invention relates to a novel compound for measuring glutathione in cell organelles, a method for preparing the novel compound, a real-time fluorescence imaging sensor for measuring glutathione in cell organelles, which comprises the novel compound, a method for fabricating the imaging sensor, and a method of measuring glutathione in cell organelles by use of the imaging sensor. When the composition comprising the compound according to the present invention is used, it can measure the antioxidant activity of the organelle mitochondria or Golgi apparatus in living cells, particularly stem cells, and can screen highly active stem cells based on the results obtained by measuring the antioxidant activity of the cell organelle.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: October 18, 2022
    Assignee: CELL2IN, INC.
    Inventors: Heun Soo Kang, Hye Mi Kim, Ji Eun Song, Myoung Jin Kim, Ki Hang Choi
  • Compounds
    Patent number: 11472798
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: October 18, 2022
    Assignee: MISSION THERAPEUTICS LTD
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Compound functioning as bromodomain protein inhibitor, and composition
    Patent number: 11466034
    Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: October 11, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd.
    Inventors: Yan Xu, Xiaofeng Xu, Jiabing Wang, Lieming Ding
  • Synthesis of disorazoles and analogs thereof as potent anticancer agents
    Patent number: 11465997
    Abstract: In one aspect, the present disclosure provides disorazole analogs of the formula: Formula (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 11, 2022
    Assignee: William Marsh Rice University
    Inventors: Kyriacos C. Nicolaou, Gabriel Bellavance, Marek Buchman, Kiran Kumar Pulukuri, Stephan Rigol
  • Compounds useful to treat influenza virus infections
    Patent number: 11466029
    Abstract: The invention provides compounds that may inhibit influenza virus replication, and are accordingly useful for treatment of viral infections caused by influenza virus. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent viral infections caused by influenza virus.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: October 11, 2022
    Assignee: NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.
    Inventors: Xiaolin Hao, Jinfu Yang
  • ERK inhibitor and use thereof
    Patent number: 11466013
    Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: October 11, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd
    Inventors: Hao Wu, Wei Gu, Xiaojing Tang, Wei Wang, Bo Zhan, Dongjie Feng, Yongxin Ke, Zhongyan Chen, Yifei Shen, Wenmao Wu, Xintao Zhao, Hong Lan, Jiabing Wang, Lieming Ding
  • Phebox ligands and methods of making same
    Patent number: 11465996
    Abstract: The present disclosure provides compounds which are useful for a number of catalytic transformations of organic molecules, non-limiting examples including dehydrogenation of alkanes. The present disclosure further relates to methods of preparing the compounds of the present disclosure.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: October 11, 2022
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Alan S. Goldman, Thomas R. Dugan
  • Isothiazolo[5,4-D]pyrimidine compound as IRAK4 inhibitor
    Patent number: 11459337
    Abstract: Disclosed in the present invention are an IRAK4 inhibitor, and an application thereof in preparation of a drug for treating IRAK4-related diseases. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 4, 2022
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Inc.
    Inventors: Yang Zhang, Jianfei Wang, Haizhong Tan, Jie Li, Jian Li, Shuhui Chen
  • Monocyclic ?-lactam compound for treating bacterial infection
    Patent number: 11459323
    Abstract: Disclosed are a class of new monocyclic ?-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated with bacterial infection. Specifically disclosed are the compounds as shown in formula (I?) and formula (II?), isomers thereof or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 4, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lianghu Gu, Wei Luo, Zhigang Huang, Charles Z. Ding, Cheng Li, Shuhui Chen
  • Heterocyclic compound
    Patent number: 11453661
    Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: September 27, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Ito, Hideyuki Sugiyama, Takeshi Yamamoto, Keiko Kakegawa, Jinxing Li, Junsi Wang, Takahito Kasahara, Masato Yoshikawa
  • KRas G12D inhibitors
    Patent number: 11453683
    Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: September 27, 2022
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
    Patent number: 11453675
    Abstract: The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrimidine-8-carboxamide compounds and variants thereof.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: September 27, 2022
    Assignee: Bial—R&D Investments, S.A.
    Inventors: Renato T. Skerlj, Elyse Marie Josee Bourque, Peter T. Lansbury, William J. Greenlee, Andrew C. Good
  • Donor-acceptor type thermally activated delayed fluorescent materials based on imidazo[1,2-f]phenanthridine and analogues
    Patent number: 11450816
    Abstract: Donor-acceptor type thermally activated delayed fluorescent emitters based on imidazo[1,2-F]phenanthridine and analogues for full color displays and lighting applications.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: September 20, 2022
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Zhi-Qiang Zhu
  • Heterocyclic compounds
    Patent number: 11447488
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 20, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tomoaki Hasui, Shinji Nakamura, Satoshi Mikami, Tohru Yamashita
  • Process for the preparation of an acesulfame in a spray reactor having a specific velocity of flow
    Patent number: 11434214
    Abstract: In general, the invention relates to a process for the preparation of acesulfame or a derivative thereof. More specifically, the invention relates to a process, to a product obtainable by the process and the use of a specified velocity of flow for improving yield in the preparation of acesulfame or a derivative thereof. The invention relates to a process for the preparation of a product, the product being 6-methyl-3,4-dihydro1,2,3-oxathiazin-4-one 2,2-dioxide or a derivative thereof, the process comprising the following steps: a. Contacting SO3 and acetoacetamide-N-sulfonic acid or a derivative thereof in a reactor with a reactor pressure to obtain the product; b. The product exiting the reactor to a region outside the reactor through an aperture at a velocity of flow higher than 0.9 m/s, the region outside the reactor having an external pressure which is lower than the reactor pressure.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: September 6, 2022
    Assignee: CHEMADVICE GMBH
    Inventor: Hans Wolfgang Ebertz
  • Methods of use and pharmaceutical combinations comprising histone deacetylase inhibitors and JAK1/2 inhibitors
    Patent number: 11433069
    Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a JAK1/2 inhibitor for the treatment of a cancer, such as a hematological cancer, in a subject in need thereof. Also provided herein are methods for treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a JAK1/2 inhibitor.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: September 6, 2022
    Assignee: University of Modena and Reggio Emilia
    Inventors: Samantha Pozzi, Maria Cosenza, Monica Civallero
  • MAGL inhibitors
    Patent number: 11434222
    Abstract: Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: September 6, 2022
    Assignee: H. LUNDBECK A/S
    Inventors: John J. M. Wiener, Cheryl A. Grice, Daniel J. Buzard, Justin S. Cisar, Olivia Delene Weber, Amy Allan, Nicholas Raffaele, Jeanne Moody, Michael B. Shaghafi